Baxter Oncology GmbH (manufacturing, quality control testing at batch release (except cell growth inhibition))

The drug is prescribed to adults for the treatment of HER2-positive breast cancer (including cases with low HER2 expression), advanced non-small cell lung cancer with HER2 mutation, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Dosage form: powder for concentrate for infusion solution

ATC: L01FD04